Foundation Medicine Taps Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Portfolio Pulse from Benzinga Newsdesk
Foundation Medicine has partnered with Repare Therapeutics to provide genomic profiling services for Repare's Phase I/Ib MYTHIC study of lunresertib. They are also exploring the development of FoundationOne®CDx as a companion diagnostic for lunresertib.
June 12, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Repare Therapeutics has partnered with Foundation Medicine to provide genomic profiling for its MYTHIC study and to develop a companion diagnostic for lunresertib.
The partnership with Foundation Medicine enhances Repare Therapeutics' capabilities in genomic profiling and companion diagnostics, which could accelerate the development and potential approval of lunresertib, positively impacting RPTX's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100